Abstract 481P
Background
Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small cell lung cancer (NSCLC). Here, we elucidate the feasibility of CGP in early-stage NSCLC, and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.
Methods
Surgically resected NSCLC samples (N=96) collected between October 2011 and April 2020 at Yonsei Cancer Center were analyzed using whole-exome sequencing (WES) (Illumina DRAGEN, v3.8) (N=96), TruSight Oncology 500 (TSO500, v2.0) (for research use only) (Illumina) (N=96), and Foundation One CDx Assay (F1CDx) (N=26) to assess the concordance in TMB calculation and targetable mutations. Programmed death-ligand 1 (PD-L1) expression were evaluated using Vectra Polaris (Akoya).
Results
The stage distribution after surgery was 80% I (N=77) and 20% II (N=19). Ninety-nine percent (N=95) were adenocarcinoma. All 96 samples were analyzed with WES and TSO500. Among these samples, 26 samples were analyzed with F1CDx. The median TMB with WES and TSO500 was 1.57 and 4.7 mut/Mb, respectively (p<0.05). The median TMB was 1.88, 5.5, 4 mut/Mb for WES, TSO500 and F1CDx, respectively (p=0.0048). Linear regression analysis of TMB values calculated using concordance correlation coefficient (CCC) between WES and TSO500 resulted in a R2=0.76. For PD-L1 tumor proportion score (TPS) of <1% (negative, N=18), ≥1% (low, N=68) and ≥ 50% (high, N=10), the CCC were 0.075, 0.79, and 0.95, respectively. The CCC values for TMB concordance were variable between 3 platforms (WES vs. TSO500, R2=0.87; WES v. F1CDx, R2=0.72; TSO500 vs. F1CDx, R2=0.84). Mutation landscape revealed EGFR mutation (51%, N=49) as the most common actionable driver mutation, comprising of L858R (N=22), E19del (N=20), and other non-common EGFR mutations (N=7).
Conclusions
F1CDx and TSO500 showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As paradigm for early-resected NSCLC continues to evolve, understanding TMB and mutation landscape may help advance clinical outcomes for this subset of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yonsei Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract